Global Infectious Disease Testing Market Insights Forecasts to 2032

• The Global Infectious Disease Testing Market Size was valued at USD 24.2 Billion in 2022.
• The market is growing at a CAGR of 5.9% from 2022 to 2032.
• The worldwide Infectious Disease Testing Market size is expected to reach USD 43.3 Billion by 2032.
• Asia Pacific is expected to grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

The Global Infectious Disease Testing Market Size is expected to reach USD 43.3 Billion by 2032, at a CAGR of 5.9% % during the forecast period 2022 to 2032.

 

Market Overview

The detection of foreign antigens or organisms is the objective of infectious illness testing, which uses test equipment and kits. The majority of diagnostic tools and kits for bacterial and viral illnesses are available. It is envisaged that molecular methods will eventually replace the majority of current testing kits. The market is growing because viral infection treatments have gotten better, the government is getting more involved, and there is a growing need for new research methods to monitor infectious illnesses. Significant market-expanding reasons include the rise in infectious illness prevalence, the emphasis on point-of-care testing instead of centralized laboratories, and growing R&D expenditures in infectious disease diagnostics. Scientific research and development efforts to create innovative technologies and techniques like mass spectrometry and next-generation sequencing (NGS), which are assisting the expansion of the infectious disease diagnostics market, are leading to the development of rapid diagnostics for disease identification. Technology integration with present manual processes leads to the creation of a completely automated process. The market for worldwide infectious disease molecular diagnostics tests now shows a high level of promise as a result of the increasing usage of molecular diagnostic technologies. The industry is also boosted by the increasing prevalence of infectious disorders worldwide.

 

Report Coverage

This research report categorizes the global infectious disease testing market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global infectious disease testing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global infectious disease testing market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

Driving Factors

The market for infectious disease testing will rise as a result of the prevalence of infectious illnesses in both developed and emerging nations. The growing number of prescriptions for infectious illness diagnostic tests is due to the diagnosis and treatment of such disorders. The demand for infectious disease diagnostics is anticipated to increase throughout the projected period as a result of these factors and the expanding trend toward preventive medicine. Also, there should be opportunities for growth for major participants in the infectious illness diagnostics market in developing nations like India, South Korea, Brazil, and Mexico. The high illness frequency, big patient population, growing medical tourism, enhanced healthcare infrastructure, and increased disposable income in these countries should be credited for this. Extensive population-based testing is necessary to enhance COVID-19 preventive and control activities. Since infectious disease diagnostics perform these tests, it had a favorable effect on this market.

 

Restraining Factors

The majority of those who are infected with infectious illnesses including HIV, malaria, and TB live in underdeveloped countries. In low- and middle-income nations, the usage of POC kits has decreased due to a lack of clinician training and poor product accessibility brought on by reduced per capita spending.

 

Market Segmentation

• In 2022 the kits & reagents segment is influencing the market with the largest market share during the forecast period.

Based on products & services, the global infectious disease testing market is segmented into kits & reagents, instruments, & software. Among these segments, the kits & reagents segment is dominating the market with the largest revenue share during the forecast period owing to the demand for PCR reagents having grown significantly, which has caused a sharp rise in the introduction of new reagents. due to a growth in point-of-care testing usage, a rise in reagent demand, and increasing research and development (R&D) activities in the pharmaceutical and biotechnology sectors. However, it is projected that the market for instruments will grow considerably throughout the forecast period as a result of rising research lab numbers and financing from both governmental and commercial organizations for the development of diagnostic tools for the biotechnology and pharmaceutical industries. loss is another prevalent side effect of multiple myeloma.

 

• In 2022, the DNA sequencing & NGS segment is dominating the largest market growth over the forecast period.

Based on the technology, the global infectious disease testing market is classified into immunodiagnostics, DNA sequencing & NGS, and PCR. Throughout these segments, the DNA sequencing & NGS segment is dominating the market. Market growth is driven by the advancement of sequencing technology and the rising applications of NGS. NGS has the potential to hasten the identification of pharmacogenetic markers for individualized treatment and the early diagnosis of disorders. The library preparation, assay design, and data analysis phases are the three most important steps in every NGS method. In the US, the New York State Department of Health treats viral illnesses like influenza via whole-genome sequencing.

 

• In 2022, the hospitals & clinical laboratories segment is leading the largest market share during the forecast period.

On the basis of end users, the global infectious disease testing market is divided into hospitals & clinical laboratories, diagnostics laboratories, & research institutes. Among these segments, the osteoblastic hospitals & clinical laboratories segment is dominating the market with the largest share during the forecast period. Its dominance can be attributed to the increase in the length of hospital stays by patients with infectious disorders. Ultimately, there is a greater demand for infectious disease point-of-care diagnostics in hospital settings. Quick test results, accessibility, and flexibility in terms of when specimen pickups should take place are all features of these systems. An aging population, rising Medicare reimbursement, and the development of new diagnostic tests all contribute to the segment's growth.

 

Regional Segment Analysis of the global infectious disease testing market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America dominates the market with the largest market share during the forecast period

 

Get more details on this report -

Request Free Sample PDF

North America is dominating the significant market growth during the forecast period because the market for infectious disease testing in North America is examined throughout the United States and Canada. The market for infectious disease testing is dominated by North America because of its elite national clinical laboratories, advanced healthcare systems, and easy access to cutting-edge technologies. The next-generation sequencing technique is now a fresh development for infectious disease diagnostics, and clinical laboratories are focusing on it. A lack of testing kits has existed in the US as a result of the coronavirus. Because of this, pathologists and clinical laboratories are actively working to create new methods for gene sequencing and diagnostic testing.

 

Asia Pacific is expected the second fastest-growing region during the forecast period

Asia Pacific is expected to grow at the highest growth rate over the forecast period due to Emerging economies like India and China being the main consumers of infectious disease testing due to rising urbanization, which produces an unclean atmosphere in cities. The Asia-Pacific and African regions represent the greatest market for infectious disease diagnostics because of the high frequency and incidence of infectious illnesses, notably bacterial infections, and sexually transmitted diseases.

 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global infectious disease testing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott Laboratories
• Becton
• Biomérieux SA
• Bio-Rad Laboratories
• Danaher Corporation
• Diasorin
• Dickinson and Company
• Luminex
• Meridian Bioscience
• Quidel
• Roche Diagnostics
• Siemens AG
• Thermo Fisher Scientific

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In February 2022, The WHO approved Roche's Actemra/RoActemra (tocilizumab) intravenous (IV) for treatment in patients with severe or significant COVID-19.

 

• In February 2022, The Allplex SARS-CoV-2 fast MDx Assay from SEEGENE was given the CE-IVD mark by the EU regulatory agency. The Allplex SARS-CoV-2 fast MDx Assay is suited for usage in airports, schools, and other large-scale institutions due to its ability to generate findings in less than 30 minutes.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Infectious Disease Testing Market based on the below-mentioned segments:

 

Global Infectious Disease Testing Market, By Product & Services

• Kits & reagents
• Instruments
• Software

 

Global Infectious Disease Testing Market, By Technology

• Immunodiagnostics
• DNA Sequencing & NGS (next-generation sequencing)
• PCR (Polymerase chain reaction)

 

Global Infectious Disease Testing Market, By End Users

• Hospitals & Clinical Laboratories
• Diagnostics Laboratories
• Research Institutes

 

Infectious Disease Testing Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa